These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 608558)

  • 1. [The clofibrate-dipyridamole combination in the prevention and therapy of arteriosclerotic vascular disease and its complications].
    Cucinotta D; Ferretti PG; Daccò L; Mazzera F
    G Clin Med; 1977; 58(11-12):475-86. PubMed ID: 608558
    [No Abstract]   [Full Text] [Related]  

  • 2. [The clofibrate-dipyridamole combination in the treatment of athero-arteriosclerotic vasculopathy].
    Parenti M; Pasquali R; Bianchi V; Barillari C; Vezzadini P
    Minerva Med; 1979 Feb; 70(8):587-93. PubMed ID: 431877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic results with combination of pyridinolcarbamate and clofibrate in atherosclerotic patients].
    Valiensi M; Riboli E; Lombardi M
    Minerva Cardioangiol; 1976 Feb; 24(2):148-54. PubMed ID: 1256654
    [No Abstract]   [Full Text] [Related]  

  • 4. [Therapeutic effect of pyridylcarbinolic ester of clofibric acid on the changes of the lipid and fibrinolytic picture in arteriosclerotic patients].
    Rugginenti
    Minerva Med; 1974 May; 65(35):1906-16. PubMed ID: 4601840
    [No Abstract]   [Full Text] [Related]  

  • 5. [Use of clofibrate and pyridinol carbamate singly or in combination in the antiarteriosclerotic therapy].
    Meciani L; Boeri S; Ricci G
    Minerva Cardioangiol; 1974; 22(7-8):512-42. PubMed ID: 4606052
    [No Abstract]   [Full Text] [Related]  

  • 6. [Checking of various hemostatic indices in patients with vascular diseases before and after treatment with inhibitors of platelet adhesiveness].
    Patrone F; Armani U; Boy E; Botta G; Boccaccio P
    Minerva Cardioangiol; 1975; 23(6-7):379-91. PubMed ID: 1143662
    [No Abstract]   [Full Text] [Related]  

  • 7. [Indications for surgical treatment and medical treatment of atherosclerosis].
    Paredero Del Bosque Martin V
    Minerva Med; 1980 Oct; 71(40):2963-7. PubMed ID: 7454082
    [No Abstract]   [Full Text] [Related]  

  • 8. [Miscleron in the treatment of patients with atherosclerosis of the coronary and cerebal vessels].
    Sivkov II; Kukes VG; Kirichenko LL; Fedosova NS; Ishmaeva KA
    Sov Med; 1971 Sep; 34(9):54-7. PubMed ID: 5121295
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapy of arteriosclerotic vasculopathies with arterial wall extract].
    Veccia F
    Clin Ter; 1967 Sep; 42(5):429-42. PubMed ID: 5617689
    [No Abstract]   [Full Text] [Related]  

  • 10. Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
    Harker LA; Hirsh J; Gent M; Genton E
    Prog Hematol; 1975; 9():229-54. PubMed ID: 766074
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical, biochemical and pathological studies of long term "clofibrate" therapy.
    el-Mehairy MM; Attia O; Nabih AE; Nassar I; Ibrahim WN
    J Trop Med Hyg; 1970 Jul; 73(7):177-81. PubMed ID: 5470220
    [No Abstract]   [Full Text] [Related]  

  • 12. [Changes induced by D-thyroxine treatment in blood lipid indices in arteriosclerotic subjects].
    Notarbartolo A; Di Fede G; Cupidi G; Rini GB
    Boll Soc Ital Biol Sper; 1974 Aug; 50(13):979-83. PubMed ID: 4463989
    [No Abstract]   [Full Text] [Related]  

  • 13. [Sulodexide treatment approach in patients with atherosclerotic vascular disease with various localizations].
    Capone-Braga M; Tellini L; Boncompagni L; Bettoni M; Burali A; Bensi A
    Clin Ter; 1987 Jan; 120(1):25-31. PubMed ID: 2973852
    [No Abstract]   [Full Text] [Related]  

  • 14. [Critical review of clinical experimentation with clofibrate in coronary disease].
    Azzena D; Astengo F
    Minerva Cardioangiol; 1973; 21(7):497-502. PubMed ID: 4756344
    [No Abstract]   [Full Text] [Related]  

  • 15. [The use of glucuronyl-glucosamino-glycan sulfate (3GS) in the treatment of cerebral and peripheral athero-arteriosclerotic pathology].
    Ciammaichella A; Solitro A; Torcia L; Arcuri P
    Clin Ter; 1978 Mar; 84(5):509-21. PubMed ID: 648104
    [No Abstract]   [Full Text] [Related]  

  • 16. [The importance of pyridinolcarbamate and clofibrate association in the treatment of arteriosclerosis].
    Pola P
    Minerva Cardioangiol; 1975 Apr; 23(4):261-9. PubMed ID: 1095958
    [No Abstract]   [Full Text] [Related]  

  • 17. [The importance of pyridinolcarbamate and clofibrate association in the treatment of arteriosclerosis].
    Pola P
    J Pharm Sci; 1975 Jan; 64(1):261-9. PubMed ID: 1094102
    [No Abstract]   [Full Text] [Related]  

  • 18. [Comparative study of the fibrinolytic activity of dimethylbiguanide in prevention of thromboembolism in patients with angiocardiopathy].
    Molino N; Belluardo C
    Rass Int Clin Ter; 1968 Jun; 48(11):687-700. PubMed ID: 5738544
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of arteriosclerotic peripheral chronic obliterating arteriopathies (A.P.C.O.) of the lower extremities with a new pharmacologic combination].
    Bagliani A; Borri P; Parravicini R
    Minerva Cardioangiol; 1975 Nov; 23(11):701-10. PubMed ID: 1223674
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of antianginal agents on the cerebral circulatory indices in cerebral arteriosclerosis].
    Eninia GI; Smeltere ES; Godlevska MA; Logina IP
    Klin Med (Mosk); 1985 Sep; 63(9):45-8. PubMed ID: 4068626
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.